Literature DB >> 15950391

Depressive disorders -- is it time to endorse different pathophysiologies?

Irina A Antonijevic1.   

Abstract

Enhanced activity of the hypothalamic-pituitary-adrenal (HPA) axis, involving elevated secretion of corticotropin-releasing hormone (CRH), is considered a key neurobiological alteration in major depression. Enhanced CRH secretion is also believed to contribute to the typical sleep alterations and the clinical presentation of major depression. While it is acknowledged that HPA overdrive and hypernoradrenergic function is associated with melancholic depression, there is growing evidence that hypoactivity of the HPA axis and afferent noradrenergic pathways is present in patients with atypical features of depression. The clinical relevance of such a differentiation is highlighted by findings which suggest distinct responses to pharmacological treatments. Moreover, it has been reported that female patients respond better to selective serotonin re-uptake inhibitors (SSRI) than tricyclic antidepressants. Interestingly, the female predominance among patients with depression seems to be restricted to the atypical subtype. Besides HPA axis activity, distinct alterations of the serotonergic system may also play a critical role for the melancholic and atypical phenotypes, namely a reduced restrained via 5-HT(1A) autoreceptors in the former and primarily reduced serotonin synthesis in the latter. Moreover, there is evidence for an immune activation in patients with depression, the extent and duration of which may be distinguishable for the melancholic and the atypical subtype. In this regard, lessons can be learned from depressive symptoms in patients with autoimmune disease, associated with different alterations of the HPA axis, and in patients undergoing cytokine therapy. In conclusion, the available data today suggest that clinically relevant differences in the underlying pathophysiology in patients with depression exist. The identification of distinct endophenotypes for major depression will not only improve our understanding of the disease, but will also contribute to more specific treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950391     DOI: 10.1016/j.psyneuen.2005.04.004

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  40 in total

1.  Neglected children, shame-proneness, and depressive symptoms.

Authors:  David S Bennett; Margaret Wolan Sullivan; Michael Lewis
Journal:  Child Maltreat       Date:  2010-08-19

Review 2.  The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Anne Maria Möller-Leimkühler; Giancarlo Giupponi; Paolo Girardi; Roberto Tatarelli; David Lester
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-20       Impact factor: 5.270

Review 3.  Neurobiological processes in adolescent addictive disorders.

Authors:  Ty S Schepis; Bryon Adinoff; Uma Rao
Journal:  Am J Addict       Date:  2008 Jan-Feb

Review 4.  [Why are there analogous disease mechanisms in chronic inflammatory diseases?].

Authors:  Rainer H Straub; Hugo O Besedovsky; Adriana Del Rey
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

5.  Depressive symptom composites associated with cortisol stress reactivity in adolescents.

Authors:  Matthew C Morris; Chrystyna D Kouros; Alyssa S Mielock; Uma Rao
Journal:  J Affect Disord       Date:  2016-12-20       Impact factor: 4.839

6.  Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex.

Authors:  Jean-Philippe Guilloux; Marianne Seney; Nicole Edgar; Etienne Sibille
Journal:  J Neurosci Methods       Date:  2011-01-26       Impact factor: 2.390

7.  Protective effect of sex on chronic stress- and depressive behavior-induced vascular dysfunction in BALB/cJ mice.

Authors:  Shyla C Stanley; Steven D Brooks; Joshua T Butcher; Alexandre C d'Audiffret; Stephanie J Frisbee; Jefferson C Frisbee
Journal:  J Appl Physiol (1985)       Date:  2014-08-14

8.  Mind matters in cancer survival.

Authors:  David Spiegel
Journal:  Psychooncology       Date:  2012-03-21       Impact factor: 3.894

Review 9.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

10.  Stress and depression: preclinical research and clinical implications.

Authors:  Alessandro Bartolomucci; Rosario Leopardi
Journal:  PLoS One       Date:  2009-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.